132 related articles for article (PubMed ID: 35918816)
21. Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy.
Jin C; Wang Y; Li Y; Li J; Zhou S; Yu J; Wang Z; Yu Y; Zhang H; Wang D; He Z; Wang Y
Int J Pharm; 2021 Sep; 607():121027. PubMed ID: 34418473
[TBL] [Abstract][Full Text] [Related]
22. Multifunctional Liposomes Remodeling Tumor Immune Microenvironment for Tumor Chemoimmunotherapy.
Li X; Luo Y; Huang Z; Wang Y; Wu J; Zhou S
Small Methods; 2023 May; 7(5):e2201327. PubMed ID: 37075716
[TBL] [Abstract][Full Text] [Related]
23. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
24. Chitosan based pH-responsive polymeric prodrug vector for enhanced tumor targeted co-delivery of doxorubicin and siRNA.
Yan T; Zhu S; Hui W; He J; Liu Z; Cheng J
Carbohydr Polym; 2020 Dec; 250():116781. PubMed ID: 33049806
[TBL] [Abstract][Full Text] [Related]
25. A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis.
Wei Z; Wang H; Xin G; Zeng Z; Li S; Ming Y; Zhang X; Xing Z; Li L; Li Y; Zhang B; Zhang J; Niu H; Huang W
Int J Nanomedicine; 2020; 15():6545-6560. PubMed ID: 32943867
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
27. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
28. Detachable Nanoparticle-Enhanced Chemoimmunotherapy Based on Precise Killing of Tumor Seeds and Normalizing the Growing Soil Strategy.
Wang L; Ding K; Zheng C; Xiao H; Liu X; Sun L; Omer R; Feng Q; Zhang Z
Nano Lett; 2020 Sep; 20(9):6272-6280. PubMed ID: 32787161
[TBL] [Abstract][Full Text] [Related]
29. A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells.
Wan J; Wang J; Zhou M; Rao Z; Ling X
J Mater Chem B; 2020 Sep; 8(34):7755-7765. PubMed ID: 32735004
[TBL] [Abstract][Full Text] [Related]
30. Laser/GSH-Activatable Oxaliplatin/Phthalocyanine-Based Coordination Polymer Nanoparticles Combining Chemophotodynamic Therapy to Improve Cancer Immunotherapy.
Huang Z; Chen Y; Zhang J; Li W; Shi M; Qiao M; Zhao X; Hu H; Chen D
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39934-39948. PubMed ID: 34396771
[TBL] [Abstract][Full Text] [Related]
31. An "AND" Logic-Gated Prodrug Micelle Locally Stimulates Antitumor Immunity.
Chen M; Wang C; Wang X; Tu Z; Ding Z; Liu Z
Adv Mater; 2024 Feb; 36(6):e2307818. PubMed ID: 37935201
[TBL] [Abstract][Full Text] [Related]
32. Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment.
Wen Y; Chen X; Zhu X; Gong Y; Yuan G; Qin X; Liu J
ACS Appl Mater Interfaces; 2019 Nov; 11(46):43393-43408. PubMed ID: 31701733
[TBL] [Abstract][Full Text] [Related]
33. Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy.
Wang Y; Wang Z; Chen B; Yin Q; Pan M; Xia H; Zhang B; Yan Y; Jiang Z; Zhang Q; Wang Y
Nano Lett; 2021 May; 21(10):4371-4380. PubMed ID: 33984236
[TBL] [Abstract][Full Text] [Related]
34. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma.
Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X
Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312
[TBL] [Abstract][Full Text] [Related]
35. Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine.
Zhang Q; Wu P; Wu J; Shou H; Ming X; Wang S; Wang B
ACS Nano; 2023 Apr; 17(8):7498-7510. PubMed ID: 37011376
[TBL] [Abstract][Full Text] [Related]
36. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
37. Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy.
Hu M; Zhang J; Kong L; Yu Y; Hu Q; Yang T; Wang Y; Tu K; Qiao Q; Qin X; Zhang Z
ACS Nano; 2021 Feb; 15(2):3123-3138. PubMed ID: 33470095
[TBL] [Abstract][Full Text] [Related]
38. Dual-responsive nanosystem based on TGF-β blockade and immunogenic chemotherapy for effective chemoimmunotherapy.
Huang X; Han L; Wang R; Zhu W; Zhang N; Qu W; Liu W; Liu F; Feng F; Xue J
Drug Deliv; 2022 Dec; 29(1):1358-1369. PubMed ID: 35506467
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
[TBL] [Abstract][Full Text] [Related]
40. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
